Structural and connectivity changes after botulinum neurotoxin therapy in blepharospasmus and hemifacial spasm
Objective: The two primary objectives of this study were to investigate the structural grey matter changes and connectivity differences between patients with BEB and HFS…Heterozygous TUBB4A knock-out impairs mitochondrial motility in human neuronal model of DYT4
Objective: To study the role of tubulin beta 4A (TUBB4A) in mitochondrial motility in isogenic induced pluripotent stem cells (iPSC)-derived neurons. Background: Heterozygous mutations in…Are we speaking the same language? A pilot study to evaluate the agreement in clinical phenotyping of children with cerebral palsy
Objective: The aim of this pilot study was determine the agreement of phenotypical classification of children with cerebral palsy among clinicians. Background: Cerebral palsy (CP)…Nursing diagnoses and interventions in rehabilitation related to antiParkinsonian pharmacotherapy
Objective: To analyze the role of nurses in antiParkinsonian pharmacotherapy based on the International Classification for Nursing Practice (ICNP®). Background: Although it is considered an…The effect of daytime working for development of sleep apnea in office workers
Objective: Nowadays sleep apnea becomes the one of the most general problem in each sphere. Every day, the role of sleep apnea in the development…Effectiveness of Lee Silverman voice treatment big on improving gait and quality of life in Parkinson’s disease patients after STN-DBS
Objective: To study effectiveness of Intensive amplitude specific exercise training of LSVT [Lee Silverman Voice Treatment] BIG on improving gait and quality of life in…Development of a nanoherbaceutical containing natural L-DOPA from mucuna pruriens for the prevention and treatment of Parkinson’s disease in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced animal model
Objective: To prepare and evaluate the nanoherbaceutical formulation containing natural L-DOPA from Mucuna pruriens against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinson's disease (PD). Background: PD is…The role of active rehabilitation measures, for maintaining the quality of life of patients after stroke with movement disorders in the general practice conditions
Objective: Assessment of the impact of active rehabilitation measures on quality of life of patients after stroke with movement disorders in primary health care. Background:…Beyond 30 years of Parkinson’s disease: A comprehensive characterization of long-surviving patients
Objective: To analyze the features of very late stage Parkinson's disease (PD) in a selected group of patients treated with bilateral subthalamic nucleus DBS (STN-DBS),…AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the motor functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of AG-0029. Background: Parkinson's disease (PD), in which there is widespread degeneration…
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 207
- Next Page »